Advertisement
UK markets closed

  • FTSE 100

    8,213.49
    +41.34 (+0.51%)
     

  • FTSE 250

    20,164.54
    +112.21 (+0.56%)
     

  • AIM

    771.53
    +3.42 (+0.45%)
     

  • GBP/EUR

    1.1655
    -0.0028 (-0.24%)
     

  • GBP/USD

    1.2550
    +0.0017 (+0.13%)
     

  • Bitcoin GBP

    49,151.98
    +2,004.06 (+4.25%)
     

  • CMC Crypto 200

    1,339.01
    +62.04 (+4.86%)
     

  • S&P 500

    5,129.30
    +65.10 (+1.29%)
     

  • DOW

    38,674.14
    +448.48 (+1.17%)
     

  • CRUDE OIL

    78.03
    -0.92 (-1.17%)
     

  • GOLD FUTURES

    2,304.90
    -4.70 (-0.20%)
     

  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

  • HANG SENG

    18,475.92
    +268.79 (+1.48%)
     

  • DAX

    18,001.60
    +105.10 (+0.59%)
     

  • CAC 40

    7,957.57
    +42.92 (+0.54%)
     
MONEY:

Best savings accounts that offer above inflation rates

Where to find a top-rated deal that works for you

BUZZ-AstraZeneca: Q4 earnings underwhelm

Reuters - UK Focus

** AstraZeneca (NYSE: AZN - news) down 2.7 pct around 1-mth lows after Q4 results come in shy of expectations

** Q4 sales fell 2 pct to $6.68 bln vs analysts' forecast of $6.79 bln; core EPS, however, expected to increase by low single-digit pct this yr

** Co also agrees to buy Actavis (NYSE: ACT - news) ' branded respiratory drug business in US & Canada

** AZN most actively traded stock on FTSE 100, with almost half of its 90-day daily avg volume having gone through

** Meanwhile, Smith & Nephew (LSE: SN.L - news) inches up 0.9 pct after posting broadly in line FY numbers

** Some fund managers reckon rally in European healthcare stocks, boosted by M&A hopes - which have been somewhat dashed, particularly in UK - has run its course Chart: http://link.reuters.com/wux63w

(RM (LSE: RM.L - news) : tricia.wright1.thomsonreuters.com@reuters.net)